Uric Acid and Long-term Outcomes in CKD

Magdalena Madero, Mark J. Sarnak, Xuelei Wang, Tom Greene, Gerald J. Beck, John W. Kusek, Allan J Collins, Andrew S. Levey, Vandana Menon

Research output: Contribution to journalArticle

250 Scopus citations

Abstract

Background: Hyperuricemia is prevalent in patients with chronic kidney disease (CKD); however, data are limited about the relationship of uric acid levels with long-term outcomes in this patient population. Study Design: Cohort study. Setting & Participants: The Modification of Diet in Renal Disease (MDRD) Study was a randomized controlled trial (N = 840) conducted from 1989 to 1993 to examine the effects of strict blood pressure control and dietary protein restriction on progression of stages 3 to 4 CKD. This analysis included 838 patients. Predictor: Uric acid level. Outcomes & Measurements: The study evaluated the association of baseline uric acid levels with all-cause mortality, cardiovascular disease (CVD) mortality, and kidney failure. Results: Mean age was 52 ± 12 (SD) years, glomerular filtration rate was 33 ± 12 mL/min/1.73 m2, and uric acid level was 7.63 ± 1.66 mg/dL. During a median follow-up of 10 years, 208 (25%) participants died of any cause, 127 (15%) died of CVD, and 553 (66%) reached kidney failure. In multivariate models, the highest tertile of uric acid was associated with increased risk of all-cause mortality (hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.07 to 2.32), a trend toward CVD mortality (HR, 1.47; 95% CI, 0.90 to 2.39), and no association with kidney failure (HR, 1.20; 95% CI, 0.95 to 1.51) compared with the lowest tertile. In continuous analyses, a 1-mg/dL greater uric acid level was associated with 17% increased risk of all-cause mortality (HR, 1.17; 95% CI, 1.05 to 1.30) and 16% increased risk of CVD mortality (HR, 1.16; 95% CI, 1.01 to 1.33), but was not associated with kidney failure (HR, 1.02; 95% CI, 0.97 to 1.07). Limitations: Primary analyses were based on a single measurement of uric acid. Results are generalizable primarily to relatively young white patients with predominantly nondiabetic CKD. Conclusions: In patients with stages 3 to 4 CKD, hyperuricemia appears to be an independent risk factor for all-cause and CVD mortality, but not kidney failure.

Original languageEnglish (US)
Pages (from-to)796-803
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume53
Issue number5
DOIs
StatePublished - May 2009

Keywords

  • Kidney disease
  • cardiovascular
  • kidney failure
  • mortality
  • outcomes
  • uric acid

Fingerprint Dive into the research topics of 'Uric Acid and Long-term Outcomes in CKD'. Together they form a unique fingerprint.

  • Cite this

    Madero, M., Sarnak, M. J., Wang, X., Greene, T., Beck, G. J., Kusek, J. W., Collins, A. J., Levey, A. S., & Menon, V. (2009). Uric Acid and Long-term Outcomes in CKD. American Journal of Kidney Diseases, 53(5), 796-803. https://doi.org/10.1053/j.ajkd.2008.12.021